| TF Name |
Cell-line |
Condition/Source |
Collections |
Species |
Identifiers |
JASPAR ID |
| AR |
LNCaP-abl (Prostate carcinoma) |
Treatment: vehicle (DMSO) of 5 uM for 4-5 days Passages: 61-64 Phenotype: AR-positive, EZH2 inhibitor -sensitive |
Permissive
Robust
|
Homo sapiens |
GSE80238
...
|
MA0007.3
|
| AR |
LNCaP-abl (Prostate carcinoma) |
Treatment: GSK126 of 5 uM for 4-5 days Passages: 61-64 Phenotype: AR-positive, EZH2 inhibitor -sensitive |
Permissive
Robust
|
Homo sapiens |
GSE80238
...
|
MA0007.3
|
| AR |
22RV1 (prostate carcinoma) |
Treatment: non-target siNT+R1881 |
Permissive
Robust
|
Homo sapiens |
GSE80742
...
|
MA0007.3
|
| AR |
22RV1 (prostate carcinoma) |
treatment: targeting ARV1/3/4/7 siARVs+R1881 |
Permissive
Robust
|
Homo sapiens |
GSE80742
...
|
MA0007.3
|
| AR |
22RV1 (prostate carcinoma) |
Treatment: targeting AR exon 7 siARFL+ ethanol |
Permissive
Robust
|
Homo sapiens |
GSE80742
...
|
MA0007.3
|
| AR |
LNCaP (prostate carcinoma) |
Treatment: Cells were harvested in log phase growth Genotype: wildtype |
Permissive
Robust
|
Homo sapiens |
GSE85558
...
|
MA0007.3
|
| AR |
LNCaP (prostate carcinoma) |
Treatment: Cells were harvested in log phase growth Genotype: HNF4G overexpression |
Permissive
Robust
|
Homo sapiens |
GSE85558
...
|
MA0007.3
|
| AR |
22RV1 (prostate carcinoma) |
Treatment: Cells were harvested in log phase growth Genotype: wildtype |
Permissive
Robust
|
Homo sapiens |
GSE85558
...
|
MA0007.3
|
| AR |
22RV1 (prostate carcinoma) |
Treatment: DHT 100nM 4 hours |
Permissive
Robust
|
Homo sapiens |
GSE86456
...
|
MA0007.3
|
| AR |
22RV1 (prostate carcinoma) |
Treatment: control |
Permissive
Robust
|
Homo sapiens |
GSE120738
...
|
MA0007.3
|
Showing 10 records in page 7
from 348 pages